Hosted on MSN

BridgeBio rises after late-stage trial win for dwarfism therapy

BridgeBio Pharma (BBIO) added ~13% in the premarket on Thursday after the company reported success in a pivotal Phase 3 trial for infigratinib, its experimental therapy for a form of dwarfism called ...
FierceBiotech

Sanofi will drop phase 2 dwarfism drug as part of rare disease clear-out

Sanofi has halted work on a phase 2 candidate for a rare growth disorder as part of a pipeline clear-out that saw the French pharma discontinue two other rare disease assets and one of its mRNA flu ...
WTEN

Physical Therapy, Dwarfism Awareness Month

GLENS FALLS, N.Y. (NEWS10) – It is Physical Therapy Awareness Month and it’s also Dwarfism Awareness Month and that’s why NEWS10 was at Glens Falls Hospital’s Rehabilitation and Wellness Center.
Reuters

US FDA extends review of Ascendis Pharma's therapy for children with dwarfism

Nov 25 (Reuters) - The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's (A71.F), opens new tab therapy for children with a rare genetic disorder that causes ...